Open-label Study to Evaluate the Safety and Tolerability of iv Lacosamide in Japanese Adults With Partial-onset Seizures
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
EP0024 is a Phase 3, multicenter, open-label study to evaluate the safety and tolerability of
intravenous (iv) lacosamide (LCM). Adjunctive iv LCM therapy (200 mg/day to 400 mg/day) will
be administered for 5 days as replacement for oral LCM tablets in Japanese adults with
partial-onset seizures.